The US government has placed an order with Merck & Co to buy 1.7 million courses of its antiviral drug...
FDA-approved drugs or experimental drugs with ample health data could be rapidly tested in humans for treatment of COVID-19 Credit: Scripps Research June 3, 2021 –...
Estos líderes, en mayor o menor medida, subestimaron la gravedad de la pandemia -- con consecuencias mortales.
Russia's Supreme Court on May 27 rejected a lawsuit from Gilead Sciences that challenged a Russian government decision to let a Russian firm develop and market...
Should growth-driven investors consider these biotech stocks? The post Trading Stocks? 5 Biotech Stocks To Watch Before June 2021 appeared first on Stock Market News, Quotes,...
Doctors Claim A Cocktail Of Cheap Drugs Could Help India Extinguish COVID Crisis Last week, we reported that several increasingly desperate communities across India have been...
The pandemic's not over yet, but these world leaders have already cemented their place in history for failing to effectively combat the deadly coronavirus. Some of...
Indian coronavirus infections and deaths held close to record daily highs on May 10, increasing calls for the government of Prime Minister Narendra Modi to lock...
India gave emergency use authorization for a Covid-19 antibody drug cocktail developed by Roche and Regeneron, expanding the company's arsenal of drugs to battle a massive...
Pfizer expects revenues from its BioNTech-partnered COVID-19 vaccine to reach an eye-watering $26 billion this year, catapulting it The post Pfizer says COVID-19 jab could rake...
In a roundup review of scientific studies recently published, a study out of RCSI University of Medicine and Health Sciences and the HSE Health Protection Surveillance...
The European Medicines Agency will conduct an accelerated review of Eli Lilly and Co.'s rheumatoid arthritis drug Olumiant for hospitalized Covid-19 patients getting oxygen, the EU...
When combined with drugs currently used to treat hepatitis C, the antiviral remdesivir is 10 times more effective in treating cells infected with SARS-CoV-2.
Biopharmaceutical company Gilead Sciences is expanding the availability of its COVID-19 treatment Remdesivir in India amid the country’s spike in cases. Gilead (GILD) is providing technical...
Indian Vaccine Makers Jack Up Prices As Outbreak Worsens; 1st COVID "Triple Mutant" Identified India's surge in COVID-19 infections and deaths, potentially driven by a convergence...
Patients with acute respiratory failure may now enroll in NIH-sponsored trial Credit: NIAID A new Phase 3 trial to test the safety and efficacy of therapeutics...
Burlingame, California-based Humanigen reported positive data from the company's Phase Ib ZUMA-19 trial of lenzilumab in patients treated with CAR-T in diffuse large B-cell lymphoma (DLBCL). Lenzilumab is...
As India Reports Record Deaths, PM Modi Warns New COVID Lockdowns Should Be "Last Resort" Once heralded by public health experts for its stringent COVID lockdowns,...
Eli Lilly and Co. And Incyte reported data from their phase 3 study of baricitinib in hospitalized COVID-19 patients. This study, called COV-BARRIER included 1525 patients...
IQVIA’s Sarah Rickwood reviews the launch of innovative medicines in 2020 and outlines three key pillars of activity The post Three pillars of post-pandemic launch excellence...
A phase 3 trial of Romark’s antiviral drug NT-300 has missed the main objective in a phase 3 The post Romark eyes FDA okay for COVID...
Credit: NIAID A clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease and low...
Gilead Sciences Inc. said on April 12 that the company decided to stop a late-stage trial of the intravenous treatment Veklury in high-risk non-hospitalized patients with...
Pubs, Gyms Reopen As England Eases COVID Lockdowns Crowds queued up outside retailers, gyms and pubs on Monday as barkeeps pulled pints and millions of English...
Eli Lilly’s JAK inhibitor Olumiant has missed its main objective in a phase 3 trial in hospitalised COVID-19 The post Lilly’s Olumiant flunks COVID-19 trial –...
Credit: Purdue University photo/ Rebecca McElhoe WEST LAFAYETTE, Ind. – New insights into the immune response to SARS-CoV-2 infections could bring better treatments for COVID-19 cases....
Eli Lilly & Incyte said their rheumatoid arthritis drug baricitinib did not meet the main goal of preventing progression to mechanical ventilation in hospitalized Covid-19 patients
By blocking human enzyme cathepsin L, chemical inhibitor K777 reduces coronavirus’ ability to infect cell lines; clinical trials are underway Credit: National Institute of Allergy and...
Emergent BioSolutions' Phase III trial of SARS-CoV-2 Immune Globulin Intravenous (Human) (COVID-HIG) to treat hospitalized patients with COVID-19 showed that the addition of the treatment to...
Relief Therapeutics Holding AG (OTC: RLFTF) is making a powerful run northbound after NeuroRx reported ZYESAMI™ met the primary endpoint in its Phase 2b/3 trial* for...